Drug Profile
Frexalimab - ImmuNext/Sanofi
Alternative Names: INX 021; SAR-441344Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator ImmuNext
- Developer Sanofi
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- Phase II Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus
Most Recent Events
- 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Multiple sclerosis (SC, IV), in 2026 or beyond (Sanofi pipeline, February 2024)
- 15 Feb 2024 Efficacy data from a phase II trial in Multiple sclerosis released by Sanofi
- 01 Feb 2024 Sanofi completes a phase II Sjogren's-syndrome trial in Sjogren's syndrome (In adults, In the elderly) in Canada, Argentina, Belgium, Chile, France, Germany, Hungary, Mexico, South Korea, Spain, Taiwan and the US (NCT04572841) (EudraCT2020-000511-77)